Breast cancer - gemcitabine (TA116)
Fast, easy summary view of NICE guidance on 'advanced breast cancer'
Gemcitabine, which is combined with another medicine called paclitaxel to treat metastatic breast cancer, is only recommended as a possible treatment for people with metastatic breast cancer in situations where two other treatments could also be used as alternatives.
Other treatments that doctors could use in the same situation are a medicine called docetaxel (given on its own) and docetaxel combined with another medicine called capecitabine.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: advanced breast cancer
This page was last updated: 05 September 2013
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.